JOSHA is a service that helps scholars, researchers, and students descover, use, and build upon a wide range of content Delhi-110067, rai.pratishtha86@gmail.com Abstract A 14-amino acid sequence within the buffalo prolactin (buPRL) protein has been identified by BLAST search as similar to that of somatostatin, the gold standard for determining anti-angiogenic activity. A synthetic peptide with the same sequence has been shown to exhibit powerful anti-angiogenic activity, possibly by functioning as a kallikrein-kinin system (KKS) antagonist. In order to further study this peptide's anti-angiogenic nature, bioinformatics tools were used to analyze its interaction with the bradykinin B1 receptor, which is a component of the KKS. Molecular docking studies were conducted in silico using structures of bradykinin B1 receptor obtained by homology modeling using SWISS-MODEL via the EXPASY web server, as well as a structure of the synthetic peptide that was modeled by the PEP-FOLD de novo modeling server. Docking studies were conducted with the bradykinin B1 structure using the structure of somatostatin and a PEP-FOLD derived structure of a scrambled version of the peptide. All the structures were validated using PDBsum and PROCHECK. Our results indicate that the peptide does form a complex with the bradykinin B1 receptor with a binding energy similar to that of the complex with somatostatin and the scrambled version of the peptide exhibits a similar effect.
Introduction

Angiogenesis
Angiogenesis has been established as the process by which new blood vessels are formed from the preexisting ones (Birbrair et al., 2014) . It is commonly known to occur in cases of animal growth, development, injury, or trauma as a steady blood supply is critical to the transportation of vital nutrients and biomolecules throughout the body. However, angiogenesis has also been known to become a major problem in cancer, as tumors can use the process of angiogenesis to grow and spread at the organism's expense (Chan-Ling 2008; Folkman 1971) .
The role of the kallikrein-kinin system (KKS) and bradykinin receptors in angiogenesis
The kallikrein-kinin system works during tissue inflammation and performs a variety of functions including cell proliferation, endothelial migration, and leukocyte activation. Evidence indicates that the system is pro-angiogenic in nature, and it functions through two cross-talking receptors, the inducible bradykinin B1 receptor (B1R) and the constitutively expressed bradykinin B2 receptor (B2R), both G-protein coupled receptors (Figure 1) (Costa, Sirois, Tannock, and Chammas, 2013) . Costa, Sirois, Tannock, and Chammas, 2013) .
Figure 1. Schematic representation of the kallikrein-kinin system (adapted from
The KKS has also been implicated in cancer migration, invasion, and metastasis due to its proangiogenic nature and ability to increase vascular permeability. A suitable KKS antagonist could be a vital therapeutic tool as it may counteract inflammation-related disorders and serve as an anti-cancer drug of sorts. However, only one such antagonist has successfully reached the market, Icatibant (HOE-140), a selective B2R antagonist, authorized for the treatment of hereditary angioedema (Costa, Sirois, Tannock, and Chammas, 2013) . Therefore, the aim of our study was to investigate whether a buffalo prolactin (buPRL) derived peptide, which has been shown to have anti-angiogenic properties, could act as a KKS antagonist. Our goal was to perform bioinformatics-based binding studies for a better understanding of the interaction between the peptide and the bradykinin B1 receptor.
Studies into the anti-angiogenic nature of peptide derivatives
Experiments have shown that peptide derivatives of physiological proteins do display anti-angiogenic activity. For instance, D and L-peptides derived from vascular endothelial growth factor receptor 2 (VEGFR-2) inhibited its autophosphorylation at nanomolar concentrations and showed potent antiangiogenic activity in a spheroid-based assay. This opened up the possibility of rational design of stable anti-angiogenic peptide inhibitors from their parent receptors (Piossek, et al., 2003) . Anti-angiogenic activity has also been demonstrated for naturally occurring Abeta peptides, which form beta-sheet aggregates that constitute a key component of senile plaques and vascular deposits in Alzheimer's disease (Paris, et al., 2004) .
Anti-angiogenic activity of endocrine hormone derivatives has also been shown. When the disulfide bonds of a nicked isoform of rat prolactin are reduced, the 16K N-terminal and 8K C-terminal sections are separated. The 16K N-terminal region of both rat and human prolactin were shown to display anti-angiogenic activity, both ex vivo and in vivo in rats and in humans (Ferrara, Clapp, and Weiner, 1991; Clapp, Martial, Guzman, Rentier-Delure, and Weiner, 1993) . In contrast, the intact and nicked isoforms of prolactin did not show any anti-angiogenic activity (Ferrara, Clapp, and Weiner, 1991) .
Another way of isolating peptide derivatives and studying them for anti-angiogenic activity was by cathepsin D digestion. The digestion of rat and human prolactin with this enzyme is reported to have produced anti-angiogenic 16K fragments (Ferrara, Clapp, and Weiner, 1991; Clapp, Martial, Guzman, Rentier-Delure, and Weiner, 1993) . Although such 16K fragments were not produced from buPRL, nor were such size isoforms naturally occurring, experiments established that lower-size isoforms that were naturally occurring, when separated and purified from the monomeric protein and from each other, displayed anti-angiogenic activity (Lee, Chaudhary, and Muralidhar, 2012) . Similarly, cathepsindigested fragments of buffalo prolactin also display anti-angiogenic activity (Lee, Majumder, Chatterjee, and Muralidhar, 2011) . In particular, a 14-amino acid synthetic peptide, which is based on a region of buPRL with sequence similarity to that of somatostatin, has also shown to be antiangiogenic (Lee, Majumder, Chatterjee, and Muralidhar, 2011) and, thus, was the focus of our study.
Objectives
1. To approximate the 3-dimensional (3D) structures of the 14-amino acid synthetic peptide, a scrambled version of the provided synthetic peptide, and the bradykinin B1 receptor, and to obtain the 3D structure of somatostatin from the PDB database. 
Methods and Techniques
• PEP-FOLD 1.5, a free web server, was used for de novo modeling of the 14-amino acid and scrambled peptides. This server is available at the Paris Diderot University's RPBS (Ressource Parisienne en Bioinformatique Structurale) Mobyle portal (http://bioserv.rpbs.univ-parisdiderot.fr/services/PEP-FOLD/)(http://mobyle.rpbs.univ-paris-diderot.fr/cgibin/portal.py#forms::PEP-FOLD3). This server allows estimation of conformations of peptides from 9 to 25 amino acids in length (Thévenet, et al., 2012; Maupetit, Derreumaux, and Tuffery, 2009; Maupetit, Derreumaux, and Tufféry, 2010 ).
• SWISS-MODEL was accessed via the EXPASY web server (http://swissmodel.expasy.org/) and was used for homology modeling of bradykinin receptor. Homology modeling is the estimation of a 3D structure of a protein on the basis of an experimentally determined structure (template) that bears some homology to it (Biasini, et al., 2014; Arnold, Bordoli, Kopp, and Schwede, 2006; Benkert, Biasini, and Schwede, 2011 ).
• Patch Dock server, beta 1.3 version, available from the BioInfo3D group at Tel Aviv University (http://bioinfo3d.cs.tau.ac.il/PatchDock/) was used for running shape-complementarity based docking simulations (Duhovny, Nussinov, and Wolfson, 2002; Schneidman-Duhovny, Inbar, Nussinov, and Wolfson, 2005 ).
• The freeware educational version of PyMol, downloaded from the Schrodinger Inc's PyMOL website (http://pymol.org), was used to visualize the protein structures.
• The FireDock server, also available from the BioInfo 3D group at Tel Aviv University (http://bioinfo3d.cs.tau.ac.il/FireDock/index.html) was used for energy analysis and refinement of docked protein results (Andrusier, Nussinov, and Wolfson, 2007) .
• The RCSB (Research Collaboratory in Structural Biology) Protein Data Bank (PDB) database (http://rcsb.org) was used for assessing the known 3D structure of somatostatin.
• The National Centre for Biotechnology Information (NCBI) protein database (http://www.ncbi.nlm.nih.gov/protein) was used for obtaining the sequences of somatostatin and the bradykinin B1 receptor.
• The PDBSum web server, maintained by the European Bioinformatics Institute (EBI), (http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/) was used for analysis, Ramachandran Plot generation, and validation of protein structure models. Specifically, PDBSum Generate was used for submission of the PDB structures of the models for analysis. This server conducted its own PROCHECK analysis for Ramachandran plot generation and validation of the submitted structures (Beer, Berka, Thornton, and Laskowski., 2014; Laskowski, et al., 1997) .
• For the bradykinin B1 receptor models, PROCHECK analysis and Ramachandran plot generation and validation were done via SWISS-MODEL.
Results
The background literature and prior experiments provided the sequences for the buPRL-derived peptide (AQGKGFITMALNSC) and the scrambled peptide (TASQGFINACGMLK). The sequence of the bradykinin B1 receptor was obtained from the NCBI Protein database. The buPRL-derived peptide sequence and 3D structure of somatostatin were directly obtained from the NCBI Protein database and the RCSB PDB databases, respectively ( Figure S1 , Supplementary Data). There were no experimentally determined 3D structures available for any of the other peptides or the bradykinin B1 receptor.
The bradykinin B1 receptor was modeled using the SWISS-MODEL web server. The sequence was entered as input, following which the software automatically began a template search and modeled the receptor structure based on the templates with various degrees of sequence similarity with the receptor. The model that was ultimately selected had a sequence identity of 28.23, coverage of 0.83, and resolution of 2.71 Angstrom. This model was also validated by PROCHECK analysis ( Figures S2-S6 , Supplementary Data).
The 3D structures of both the buPRL-derived peptide and its scrambled version were obtained via the PEP-FOLD de novo modeling server. The sequences of each peptide were entered as input, and five structures were given by the server as output for each peptide. Based on PROCHECK validation, one structure was selected for each peptide to be used for molecular docking (Figures S7-S12, Supplementary Data).
Molecular docking was performed using the PatchDock web server for the interactions between Bradykinin B1 receptor and somatostatin, Bradykinin B1 receptor and buPRL-derived peptide, and Bradykinin B1 receptor and scrambled peptide. This server was chosen for its user-friendly nature, as it only requires the PDB structures of the receptor and ligand as input, and gives a set of docked complexes sorted by geometric score as output. The top ten results for each docking experiment were then sent to the FireDock web server for refinement and energy analysis. Shown below are the FireDock analyses of the binding energies of each of the docking complexes, along with a PyMOL visualization of the top-ranked docking complexes for each peptide (Figures 3-9) . 
Discussion and Conclusions
Molecular docking studies between the peptides and the bradykinin B1 receptor show that the buPRLderived peptide binds to the receptor at its active site, which is the same site where somatostatin binds.
The scrambled peptide also seems to bind in the proximity of the active site, but in a different orientation. The most stable complexes formed between the bradykinin B1 receptor and each of the peptides had the following free energy values: -46.14 kJ for bradykinin B1 receptor and somatostatin, -48.57 kJ for bradykinin B1 receptor and buPRL-derived peptide, and -45.81 kJ for bradykinin B1 receptor and scrambled peptide. Though the differences in binding energies of the complexes support the hypothesis that the buPRL-derived peptide's more potent anti-angiogenic activity is due to its stronger affinity for the bradykinin B1 receptor, these differences are also surprisingly low. The most striking inference from this would be that even the scrambled peptide would be capable of forming complexes with the bradykinin B1 receptor that would be just as stable as the complexes formed between somatostatin and the bradykinin B1 receptor. This raises many pertinent questions such as: how this scrambled peptide interacts with the bradykinin B1 receptor and what effects it could have on the kallikrein-kinin system; how will the scrambled peptide affect the physiology of an animal; does it function as a bradykinin receptor agonist or antagonist; and, finally, are its effects pro-angiogenic or anti-angiogenic? Wet lab experiments including binding assays with bradykinin receptor, as well as assays testing angiogenesis, such as the CAM assay, tube formation assay, and wound healing assay could provide some answers in this regard.
Many other questions were also raised by the findings of this study. For instance, our results contradict those of Lee et al (2011) , which affirmed that the buPRL-derived peptide does not form a helix. According to their models, which were generated using SWISS-MODEL and Bhageerath, the 14-amino acid region within the buPRL structure that forms the basis of the synthetic peptide actually exists as a loop, and not as a helix (Jayaram, et al., 2006) (Lee, Majumder, Chatterjee, and Muralidhar, 2011) . In our study, de novo modeling of the peptide was done using the PEP-FOLD server to see whether it retained its loop conformation when freed from its linkage to the buPRL monomer. The structure that was selected for molecular docking did not retain the loop conformation and, in fact, had a helical conformation. This opens up many avenues for discussion concerning the effect of such a conformational change on the peptide function, as the intact buPRL does not have any anti-angiogenic activity. Proper experimental determination of the structure of this peptide in solution might provide more clarity on this issue and validate the findings. Moreover, it is currently unknown whether a biomolecule similar to this synthetic peptide actually exists as a physiological protein. Using protein isolation and purification techniques, along with specific detection assays such as western blotting with an antibody specific for the synthetic peptide, would be a good way to begin the search for such a biomolecule.
The results also indicate that there are negligible conformational changes between the unbound and bound peptides, though more refined overlapping analysis needs to be done before a definite conclusion is reached. The apparent lack of a conformational change could also be a result of limitations of the shape-complementarity based approach of PatchDock.
Some concessions were made regarding experimental errors, particularly concerning the Ramachandran maps of the PEP-FOLD predicted structures of the bu-PRL derived synthetic peptide, as none of the maps showed more than 80% of the residues in the most favored region. As PEP-FOLD attempts de novo modeling of peptide sequences, it is likely more error-prone than homology modeling.
Further courses of action can be taken to better ascertain the nature of the interactions between the buPRL-derived peptide, the scrambled version of the peptide, and the bradykinin B1 receptor.
These include bioinformatics-driven analysis of the amino acid residues involved in receptor-peptide binding and their chemical interactions, which can be done using LigPlot + (Laskowski and Swindells, 2011) as well as wet lab experiments to test protein-protein interactions. Mutant peptides could be synthesized for such experiments to test the validity of the bioinformatics predictions in this regard. 
